Holen Sie sich die Stockscreener-App
569.54
2.40%
13.34
Handel nachbörslich:
569.54
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$556.20
Offen:
$564.94
24-Stunden-Volumen:
446.21K
Relative Volume:
0.70
Marktkapitalisierung:
$44.93B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$1.10B
KGV:
41.91
EPS:
13.591
Netto-Cashflow:
$1.06B
1W Leistung:
+3.09%
1M Leistung:
+3.27%
6M Leistung:
-17.19%
1J Leistung:
+0.54%
1-Tages-Spanne:
$564.94
$578.55
1-Wochen-Bereich:
$534.36
$578.55
52-Wochen-Spanne:
$518.55
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, IQV, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
569.54 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
576.41 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.05 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IQV
Iqvia Holdings Inc
|
242.94 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
140.54 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Citigroup | Neutral |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
IDEXX Releases 2025 Corporate Responsibility Report Highlighting Innovation and Sustainability Progress - Yahoo Finance
IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals - Business Wire
IDEXX Laboratories Inc (IDXX) Balance Sheet - TradingKey
Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings - TradingView
IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention - Yahoo Finance
IDXX|IDEXX Laboratories Inc|Price:544.320|Chg%:+4.955 - TradingKey
IDEXX Laboratories stock holds firm on recurring diagnostics demand - Ad-hoc-news.de
IDEXX Laboratories, Inc. Revenue Breakdown – NASDAQ:IDXX - TradingView
IDEXX Laboratories stock trades near record levels as diagnostics growth supports valuation - Ad-hoc-news.de
IDEXX Laboratories Inc (IDXX) Income Statement - TradingKey
IDEXX Laboratories Inc (IDXX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IDEXX Laboratories Inc (IDXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IDEXX Laboratories Inc (IDXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IDEXX Laboratories, Inc. (IDXX) Stock Price, News, Quote & History - Yahoo! Finance Canada
IDEXX Laboratories Inc (IDXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IDEXX Laboratories Inc (IDXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - 富途牛牛
IDXX|IDEXX Laboratories Inc|Price:556.100|Chg%:+11.780 - TradingKey
IDEXX Laboratories stock trades near record levels as recurring diagnostics revenue supports valuati - Ad-hoc-news.de
IDEXX Laboratories Inc (IDXX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
Idexx Could Feel Chill as Pet Owners Face Rising Cost of Living - Morningstar
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IDEXX stock trades near record territory as recurring diagnostics revenue supports double digit grow - AD HOC NEWS
IDXX: Idexx Laboratories Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
IDEXX Laboratories stock holds steady as earnings metrics shape the outlook - AD HOC NEWS
IDXX|IDEXX Laboratories Inc|Price:539.180|Chg%:-0.185 - TradingKey
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories stock trades near record range as recurring veterinary revenue supports margins - AD HOC NEWS
IDEXX Laboratories stock stays anchored to its diagnostics growth - Ad-hoc-news.de
IDEXX Laboratories, Inc. (IDXX): Investor Outlook Reveals 24.85% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews
IDEXX Laboratories stock trades near record levels as veterinary diagnostics growth supports valuati - Ad-hoc-news.de
IDEXX Laboratories earnings preview: What to expect - MSN
IDEXX Laboratories Inc. stock underperforms Friday when compared to competitors - MarketWatch
New diagnostic test for kidney injury - DVM360
Global Livestock Monitoring Market to Reach $10.3 Billion by 2030, Driven by Digital Agriculture Transformation - GlobeNewswire Inc.
IDEXX Laboratories stock trades near record levels as companion animal diagnostics drive growth - Ad-hoc-news.de
IDEXX Laboratories (IDXX) Could Be 19% Undervalued After Stifel Flags Better Pet Health Trends - Sahm
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
Idexx Laboratories (IDXX) Shows Promising Growth Potential - GuruFocus
Is IDEXX Laboratories Inc (IDXX) a Bargain After 4.2% Drop? GF V - GuruFocus
Why IDEXX Laboratories (IDXX) Stock Is Down Today - Moomoo
Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating - Moomoo
Donald TrumpIDEXX LABS UNSOLICITED Trump Trade on Mar. 23, 2026 - Quiver Quantitative
IDEXX Laboratories stock holds steady as diagnostics demand supports long-term growth - ad-hoc-news.de
IDEXX Laboratories Earnings Preview: What to Expect - Barchart.com
IDEXX Laboratories focuses on diagnostics growth. Investors watch demand trends - ad-hoc-news.de
IDEXX Laboratories extends its diagnostics reach as a key S&P 500 health-tech name - ad-hoc-news.de
IDEXX Laboratories Does Not Need More Vet Visits, But It Needs More Tests Per Visit (IDXX) - Seeking Alpha
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
13.94%
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):